Zinnat 125mg/5ml Granules for Oral Suspension

  • Name:

    Zinnat 125mg/5ml Granules for Oral Suspension

  • Company:
    info
  • Active Ingredients:

    Cefuroxime Axetil

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 20/03/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 20/3/2019

Click on this link to Download PDF directly

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Zinnat 250mg Film-Coated Tablets Active Ingredients Cefuroxime Axetil
Medicine Name Zinnat 250mg/5ml Granules for Oral Suspension. Active Ingredients Cefuroxime Axetil
Medicine Name Zinnat 500mg Film-Coated Tablets Active Ingredients Cefuroxime Axetil
Medicine Name Zovirax 200 mg Dispersible Tablets Active Ingredients Aciclovir
Medicine Name Zovirax 200 mg/5 mL Oral Suspension Active Ingredients Aciclovir
Medicine Name Zovirax 5% w/w Cream Active Ingredients Aciclovir
Medicine Name Zovirax 800 mg Dispersible Tablets Active Ingredients Aciclovir
Medicine Name Zovirax Double Strength Suspension Active Ingredients Aciclovir
Medicine Name Zovirax IV 250mg Active Ingredients Aciclovir sodium
Medicine Name Zovirax® 30 mg/g Eye Ointment Active Ingredients Aciclovir
Medicine Name Zyban 150 mg prolonged release tablets Active Ingredients Bupropion Hydrochloride
126 - 136 of 136 items.Total: 6 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 20 March 2019 PIL

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product contains
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 20 March 2019 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

2. Qualitative and Quantitative Composition: Addition of excipients with known effects
3. Pharmaceutical Form: Amended wording removed description of granules
4.4 Special warnings and precautions for use: Addition of information about excipients
6.1 List of excipients: Amendment to the list of excipients and addition of corresponding E numbers
6.2 Incompatibilities: Addition of positive Coombs' test
6.3 Shelf Life: Formatting change to include reconstituted and unconstituted storage conditions
6.4 Special precautions for storage: formatting change to only mention a sentence stating the storage temperature
6.5 Nature and contents of container: Updated pack size

Updated on 8 February 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 8 February 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.2: Formatting corrections
Section 4.4: Alignment of sucrose statements with MR Annexes (125 mg/5 ml SPC only)
Section 5.1: Spelling correction
Section 10: Update of date of revision of the text

Updated on 22 December 2017 SmPC

Reasons for updating

  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 6.6 -Update of reconstitution instructions
Section 10 - Update of Date of Revision of the Text

Updated on 21 December 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 21 December 2017 PIL

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 19 January 2016 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.5 - Nature and contents of container
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC:

Section 4.2 – updated dosing recommendation wording for clarity, minor typographical amendments

Section 4.8 – addition cross-reference to Section 4.4 (500mg tablet only)

Section 5.1 – updated Staphylococcus spp. resistance category

Section 5.2 – minor typographical amendments, alignment with QRD template

Section 5.3 – minor typographical amendments,

Section 6.5 - minor typographical amendments

Section 7 – IE MAH address change

Updated on 18 January 2016 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details
  • Change to improve clarity and readability

Updated on 16 July 2015 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7 - change to Ireland MAH address

Updated on 15 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 13 March 2015 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8- administrative changes and addition of reporting details.
Section 5.1 update to the Microbiological susceptibility table

Updated on 12 March 2015 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to side-effects
  • Change to further information section
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 28 January 2014 SmPC

Reasons for updating

  • Change due to harmonisation of SPC

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change due to harmonisation or user testing of the patient leaflet

Updated on 27 January 2014 PIL

Reasons for updating

  • Change due to harmonisation of PIL
  • Change due to user-testing of patient information

Updated on 8 September 2011 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 21 January 2010 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company



125mg Granules for Oral Suspension

 

1.       NAME OF THE MEDICINAL PRODUCT

 

Zinnat 125mg/5ml Granules for Oral Suspension

 

2.       QUALITATIVE AND QUANTITATIVE COMPOSITION

 

Reconstitution of multidose bottles as directed yields a suspension containing 125mg of cefuroxime (as cefuroxime axetil) in each 5ml.

 

Each Sachet contains 125mg granules of cefuroxime (as cefuroxime axetil) for single dose administration when reconstituted.

 

Excipients: Contains approximately 3.062 g of sucrose and 21 mg of aspartame (E951) per dose.

 

For a full list of excipients, see section 6.1.

 

6.2     Incompatibilities

 

The reconstituted suspension or granules should not be mixed with hot liquids.

 

6.4     Special Precautions for Storage

 

Unconstituted granules: Do not store above 30°C.

Reconstituted suspension (multi dose bottles): must be refrigerated between 2 and 8°C Store in a refrigerator at 2oC to 8oC.

 

6.6     Instructions for Use and Handling

Reconstitution with water produces a white to off white fruit flavoured suspension.

 

Multi dose bottle: Always shake bottle vigorously before taking the medication.

The reconstituted suspension when refrigerated between 2 and 8°C can be kept for up to 10 days.

 

If desired, Zinnat suspension can be further diluted from multidose bottles in cold fruit juices, or milk drinks and should be taken immediately.

 

Directions for reconstituted suspension in multidose bottles:

 

1.      Shake the bottle to loosen the granules. Remove the cap.

2.      Add the total amount of water (27ml) to the bottle as stated on label. Replace the cap.

3.      Invert the bottle and rock the bottle vigorously (for about 15 seconds) as shown below.

4.      Turn the bottle into an upright position and shake vigorously.

5.      Refrigerate immediately at between 2 and 8C.

 

Directions for reconstituting suspension from sachets:

 

1)      Empty granules from sachet into a glass.

2)      Add a small volume of water (approx. 10ml).

3)      Stir well and drink immediately.

 

The reconstituted suspension or granules should not be mixed with hot liquids.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Updated on 12 January 2010 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to storage instructions

Updated on 14 November 2007 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4 Special Warnings and Precautions for Use

 

[…]

 

As with other antibiotics, prolonged use of cefuroxime may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of non-susceptible organisms (e.g. Candida, Enterococci and Clostridium difficile), which may require interruption of treatment.

 

[…]

 

4.8 Undesirable Effects

 

[…]

 

Infections and infestations

Common: Candida overgrowth from prolonged use.

 

[…]

Updated on 3 November 2006 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.5 Interaction with Other Medicaments and Other Forms of Interaction

Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food.

In common with other antibiotics, cefuroxime axetil may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.

As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil. This antibiotic does not interfere in the alkaline picrate assay for creatinine.

 

4.8

........Infections and infestations

Candida overgrowth from prolonged use...............

Updated on 3 November 2006 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 23 May 2006 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 28 March 2006 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 28 March 2006 SmPC

Reasons for updating

  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 4 August 2005 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 17 August 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 16 June 2004 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 3 July 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)